Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Elevated Lipoprotein(a) Clinical Trial

Official title:
A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)

Status Completed

Clinical Trial Summary

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Elevated Lipoprotein(a)

Clinical Trial Details

NCT number	NCT02414594
Study type	Interventional
Source	Ionis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	April 2015
Completion date	February 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03070782` - Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease	Phase 2
Completed	`NCT02160899` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)	Phase 2
Completed	`NCT03392051` - Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel	Phase 1
Completed	`NCT03426033` - Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin	Phase 1